Director Bruno Lucidi filed a Form 144 notice with the SEC on November 19, 2026, disclosing a proposed sale of 22,619 shares of Atea Pharmaceuticals, Inc. common stock acquired through a stock option exercise.
Key Highlights
- Proposed sale size: 22,619 shares of common stock, with an aggregate market value of $89,219.37, according to the filing.
- Acquisition method: The shares were acquired via a stock option exercise from the issuer on November 19, 2026, with payment made in cash.
- Approximate sale date: November 19, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Prior sales: The filing discloses a sale of 6,741 shares of common stock on November 17, 2026, with gross proceeds of $27,189.82, within the preceding three months.
- Shares outstanding: The filing states 80,304,145 shares of common stock outstanding at the time of the notice.
- Exchange listing: The shares are listed on NASDAQ, as stated in the filing; Atea Pharmaceuticals, Inc. carries SEC file number 001-39661.
Lucidi Form 144 Notice: Stock Option Exercise and Proposed Sale at Atea Pharmaceuticals
Bruno Lucidi, a director of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), filed a Form 144 notice dated November 19, 2026, disclosing his intent to sell 22,619 shares of the company's common stock. According to the filing, the shares were obtained through a stock option exercise from the issuer on November 19, 2026, with the full purchase price paid in cash on the same date.
The filing reports an aggregate market value of $89,219.37 for the proposed sale. The designated broker for the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The approximate date of sale is listed as November 19, 2026, on NASDAQ.
As required under Form 144, the filing also discloses securities sold by Lucidi in the prior three months. The filing states that 6,741 shares of common stock were sold on November 17, 2026, generating gross proceeds of $27,189.82. The total shares of common stock outstanding are reported as 80,304,145. The filing carries the standard Rule 144 representation that the filer "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."
What Was Disclosed
Atea Pharmaceuticals director Bruno Lucidi filed a Form 144 notice on November 19, 2026, proposing to sell 22,619 shares acquired via stock option exercise, with an aggregate market value of $89,219.37, through Morgan Stanley Smith Barney LLC on NASDAQ.



Please wait processing your request...